Estradiol (E2) is the “core regulator” of female physiological functions. Physicians often use the six-hormone panel for a comprehensive assessment and diagnosis, particularly for reproductive issues. The six-hormone panel precisely identifies "abnormal nodes" within the endocrine system. Its core value lies in transforming vague symptoms such as 'menstrual irregularities', 'infertility' and 'endocrine disorders' into quantifiable data on hormonal anomalies. This provides scientific evidence for diagnosing diseases, formulating treatment plans, and monitoring their efficacy, thereby preventing misdiagnosis or mistreatment resulting from 'empirical diagnosis and treatment'.

As a core member of the oestrogen family, estradiol (E2) exhibits level fluctuations that are directly linked to multiple physiological dimensions, including reproductive health, endocrine balance and bone metabolism. It is a key diagnostic indicator in gynaecology, reproductive medicine, endocrinology and related fields. The Chemiluminescent Estradiol Assay Kit uses advanced chemiluminescent immunoassay technology to provide the key advantages of 'high sensitivity, high specificity, and rapid efficiency'. It accurately measures estradiol concentrations in serum and plasma, providing reliable data for diagnosing diseases, monitoring treatments, and assessing health. This makes it an invaluable diagnostic tool in clinical laboratories.

As the primary estrogen, estradiol (E2) requires highly efficient and accurate measurement due to its significant clinical importance. Leveraging advanced chemiluminescent immunoassay technology, chemiluminescent assay kits offer the key advantages of 'high sensitivity', 'high specificity' and 'rapid efficiency'. They can accurately quantify estradiol concentrations in serum and plasma, providing reliable data to support disease diagnosis, therapeutic monitoring, and health assessment. These kits have become an indispensable diagnostic tool in clinical laboratories.

With a detection limit as low as 5 pg/mL, it can detect even the slightest changes in oestrogen levels within physiological ranges. Whether used to monitor pubertal development, track perimenopausal hormone fluctuations or evaluate follicular development in assisted reproduction, it provides accurate data, preventing misdiagnosis or missed diagnoses caused by insufficient sensitivity.

It is designed with a monoclonal antibody that specifically targets the molecular structure of oestradiol. The antigen-antibody binding system is also rigorously screened to effectively avoid interference from structural analogues such as oestrone and oestriol, as well as common clinical interferents (e.g. haemoglobin, bilirubin and rheumatoid factor).

It is compatible with mainstream, fully automated chemiluminescence analysers, eliminating the need for complex manual procedures. Samples undergo automated loading, reaction, detection and interpretation as part of a single, integrated process. It is equipped with comprehensive calibration standards, quality control materials and standard operating procedures (SOPs) to minimise human error and enable quick mastery, even by beginners.

The reagent has a shelf life of up to 18 months, and the coefficient of variation (CV) is ≤5% within batches and ≤8% between batches, guaranteeing the consistency and comparability of test results across different batches and laboratories.

Reproductive Health Field: Assists in diagnosing gynecological conditions such as polycystic ovary syndrome, premature ovarian failure and amenorrhea. Monitors ovulation cycles to provide follicular development assessments for individuals preparing for pregnancy. In assisted reproductive technologies, dynamically monitors estrogen levels to guide dosage adjustments of ovulation-inducing medications.

Diagnosis of Endocrine Disorders: Identifying conditions associated with abnormal estrogen secretion, such as precocious puberty, menopausal syndrome and hormone imbalances secondary to thyroid dysfunction. This provides data to support clinical interventions.

Health screening and chronic disease management: This is suitable for routine health screening in adult women and enables the early detection of hormonal imbalances. It also monitors the efficacy of treatment and the risk of recurrence in patients with hormone-dependent tumors, such as breast and endometrial cancers.

Other scenarios: Estradiol (E2) promotes osteoblast activity and inhibits osteoclast function to maintain bone density. In elderly males, declining testosterone levels lead to reduced E2 synthesis, increasing the risk of decreased bone density and predisposing them to osteoporosis. It is important to assess osteoporosis risk, as estrogen plays a crucial regulatory role in bone metabolism, and to guide hormone replacement therapy dosage adjustments to ensure treatment safety and efficacy.

The chemiluminescent estradiol assay kit enables the precise detection of estradiol (E2) concentrations：

✓ Upstream lesion localization: Combined with FSH/LH levels to assess HPO axis function (e.g. low E2 + high FSH indicates premature ovarian failure, while low E2 + low FSH suggests pituitary insufficiency).

✓ Midstream functional assessment. Monitoring peak E2 levels to determine ovulation timing and guide ovulation induction medication in assisted reproductive technologies.

✓Downstream treatment guidance: During hormone replacement therapy, adjust progesterone levels to avoid the risk of endometrial hyperplasia caused by excessively high levels of unopposed estrogen.

In summary, estradiol (E2) is essential for reproductive health, endocrine function and bone health. The E2 chemiluminescent immunoassay kit provides clinicians with a more reliable diagnostic solution by delivering precise and efficient test results. Every test provides a solid foundation for safeguarding health!